Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Up Following Earnings Beat

Autolus Therapeutics plc (NASDAQ:AUTL) shares gapped up prior to trading on Thursday following a better than expected earnings announcement. The stock had previously closed at $1.94, but opened at $2.01. Autolus Therapeutics shares last traded at $1.92, with a volume of 220,321 shares trading hands.

The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.12.

Analyst Upgrades and Downgrades

Separately, Needham & Company LLC reiterated a “buy” rating and issued a $10.00 price target on shares of Autolus Therapeutics in a research note on Monday, January 13th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $10.40.

Institutional Investors Weigh In On Autolus Therapeutics

Several institutional investors have recently made changes to their positions in the stock. Jane Street Group LLC acquired a new position in Autolus Therapeutics in the 4th quarter valued at $26,000. Barclays PLC raised its stake in Autolus Therapeutics by 1,094.3% in the fourth quarter. Barclays PLC now owns 11,859 shares of the company’s stock valued at $28,000 after purchasing an additional 10,866 shares in the last quarter. Dumont & Blake Investment Advisors LLC bought a new stake in Autolus Therapeutics during the fourth quarter worth about $35,000. Arkadios Wealth Advisors bought a new stake in Autolus Therapeutics during the fourth quarter worth about $47,000. Finally, Capstone Investment Advisors LLC acquired a new stake in Autolus Therapeutics during the third quarter worth about $51,000. 72.83% of the stock is currently owned by institutional investors.

Autolus Therapeutics Stock Performance

The firm’s fifty day simple moving average is $2.05 and its 200 day simple moving average is $2.94. The stock has a market capitalization of $511.17 million, a P/E ratio of -1.60 and a beta of 2.07.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.